Abstract Library

#4628 Triple negative breast neuroendocrine carcinoma in older patient: A rare entity

Introduction: Neuroendocrine breast carcinoma is a rare histological form of breast cancer, that represent 0.1% of all breast cancers and is recognised by the World Health Organization as a distinct entity. Characterised by a non-specific clinical and radiological presentation. Therapeutic management is not codified and is usually superimposed on that of classical breast cancer.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: neuroendocrine carcinoma, triple negative breast cancer, platinum-based combination therapy,

#4600 Artificial intelligence in predicting neuroendocrine tumour (NET) outcomes: A model-based prognostic approach

Introduction: Neuroendocrine tumours (NETs) vary widely in clinical behaviour, complicating prognosis. Traditional models often struggle with accuracy due to the complexity of NETs. Artificial intelligence (AI) offers tools for enhanced prognostic precision by analysing complex datasets. This study explores an AI-driven approach to predict outcomes in NET patients at Cantonment General Hospital, Pakistan.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: artificial intelligence, machine learning, Precision medicine, Personalised treatment,

#4544 Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)

Introduction: Data derived from the study of intertumour heterogeneity have led to propose that PanNET evolution may start either from beta cells with good prognosis, or from alpha cells with sequential alterations of MDA (MENIN-DAXX/ATRX) leading to more aggressive lesions.

Conference:

Presenting Author: Awan Z

Authors: Awan Z, Bourdeleau P, Epée J, Ps H, Tihy M,

Keywords: Pancreatic neuroendocrine tumour, Heterogeneity, Tumour microenvironment,

#4535 Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

Introduction: In patients (pts) with an advanced well-differentiated (WD-NET) with a Ki-67>10% and ≤20% (“G2 high”), chemotherapy (ChT) or targeted therapies are the preferred first-line palliative options. Somatostatin analogues (SSAs) may offer an alternative, yet randomised evidence is lacking.

Conference:

Presenting Author:

Authors: Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N,

Keywords: somatostatin analogue, SSA, non-SSA, Grade 2 well-differentiated neuroendocrine tumour, WD-NET,

#4504 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. CAPTEM as first-line (1L) treatment for advanced grade 3 (G3) gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Introduction: The NETTER-2 trial showed a significant progression-free survival (PFS) benefit with 1L 177Lu-DOTATATE vs. high dose octreotide for patients with advanced G2/G3 GEP-NETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments for patients with G3 GEP-NETs, such as capecitabine + temozolomide (CAPTEM), hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Deshayes E

Authors: Deshayes E, Capdevila J, Gerard L, Navalkissoor S, Srirajaskanthan R,

Keywords: gastroenteropancreatic neuroendocrine tumour, [177lu]lu-dotatate, capecitabine, temozolomide, matching adjusted indirect comparison,